Abstract
Pazopanib is an approved treatment for renal cell carcinoma and a second-line treatment for nonadipocytic soft-tissue sarcoma. However, its clinical e......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
